Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: SpectraCure AB

Market Cap 67.79M 7.19M 6.21M 5.71M 5.36M 10.04M 688M 10.2M 26.34M 333M 26.99M 26.41M 1.16B P/E Ratio 2024
-10.6x
P/E Ratio 2025 -0.79x
Enterprise Value 57.05M 6.05M 5.22M 4.81M 4.51M 8.45M 579M 8.58M 22.17M 280M 22.71M 22.22M 976M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
85.17%
Yield 2024 *
-
Yield 2025 -
1 day-2.14%
1 week-20.91%
Current month-15.14%
1 month+80.00%
3 months+29.13%
6 months-25.00%
Current year-23.75%
1 week 0.11
Extreme 0.1064
0.15
1 month 0.06
Extreme 0.0583
0.17
Current year 0.06
Extreme 0.0583
0.17
1 year 0.06
Extreme 0.0583
0.38
3 years 0.06
Extreme 0.0583
6.6
5 years 0.06
Extreme 0.0583
13.19
10 years 0.06
Extreme 0.0583
45.15
Manager TitleAgeSince
Chief Executive Officer 54 2025-09-30
Director of Finance/CFO - 2026-05-31
Chief Tech/Sci/R&D Officer - 2025-10-06
Director TitleAgeSince
Director/Board Member 63 2012-08-30
Director/Board Member 72 2021-12-31
Chairman 74 2021-12-31
Date Insider Type Main position Quantity % Market Cap.
23-05-25Buy

Chairman

25,000 0.0257%
22-08-29Buy

Director

25,000 0.0257%
22-07-08Sell

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-20.91%-66.82%-98.14% 7.31M
0.00%+4.83%+53.21%+52.23% 1.55B
+1.82%-4.52%-39.59%-43.30% 326M
-1.31%-9.60%-3.42%-50.87% 56.21M
Average -0.41%-7.13%-14.15%-35.02% 485.51M
Weighted average by Cap. +0.26%+2.85%+35.56%+32.67%

Financials

2024 2025
Net sales - -
Net income -23M -2.44M -2.11M -1.94M -1.82M -3.41M -234M -3.46M -8.94M -113M -9.16M -8.96M -394M -56.08M -5.95M -5.13M -4.73M -4.43M -8.31M -570M -8.44M -21.79M -275M -22.33M -21.85M -959M
Net Debt -13.13M -1.39M -1.2M -1.11M -1.04M -1.94M -133M -1.98M -5.1M -64.42M -5.23M -5.11M -225M -10.74M -1.14M -983K -905K -848K -1.59M -109M -1.62M -4.17M -52.68M -4.27M -4.18M -184M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
26-06-11 0.1188 kr -2.14% 1,017,910
26-06-10 0.1214 kr -5.75% 1,424,137
26-06-09 0.1288 kr -0.46% 409,484
26-06-08 0.1294 kr -7.57% 2,487,295
26-06-05 0.1400 kr -2.10% 927,510
  1. Stock Market
  2. Stocks
  3. SPEC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!